TIAA CREF Investment Management LLC increased its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 9.3% during the first quarter, Holdings Channel reports. The fund owned 107,548 shares of the biopharmaceutical company’s stock after buying an additional 9,162 shares during the period. TIAA CREF Investment Management LLC’s holdings in Cytokinetics, were worth $1,382,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC raised its position in shares of Cytokinetics, by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 189 shares in the last quarter. American International Group Inc. raised its position in shares of Cytokinetics, by 7.1% in the first quarter. American International Group Inc. now owns 20,852 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 1,380 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Cytokinetics, by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 53,278 shares of the biopharmaceutical company’s stock worth $647,000 after buying an additional 2,025 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Cytokinetics, during the first quarter worth $156,000. Finally, Wells Fargo & Company MN raised its position in shares of Cytokinetics, by 46.9% in the first quarter. Wells Fargo & Company MN now owns 39,308 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 12,542 shares in the last quarter. Institutional investors own 56.50% of the company’s stock.

Shares of Cytokinetics, Incorporated (NASDAQ CYTK) traded up 2.263% during trading on Monday, hitting $12.425. The stock had a trading volume of 36,818 shares. Cytokinetics, Incorporated has a 12 month low of $8.51 and a 12 month high of $17.20. The stock has a 50 day moving average of $13.43 and a 200 day moving average of $13.03. The company’s market cap is $666.80 million.

Cytokinetics, (NASDAQ:CYTK) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. Equities analysts forecast that Cytokinetics, Incorporated will post ($2.08) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “TIAA CREF Investment Management LLC Has $1.38 Million Position in Cytokinetics, Incorporated (CYTK)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/14/tiaa-cref-investment-management-llc-has-1-38-million-position-in-cytokinetics-incorporated-cytk.html.

A number of brokerages have weighed in on CYTK. Zacks Investment Research upgraded Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Monday, August 7th. Cowen and Company restated a “buy” rating and issued a $19.00 target price on shares of Cytokinetics, in a research note on Friday, August 4th. HC Wainwright set a $26.00 target price on Cytokinetics, and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Morgan Stanley began coverage on Cytokinetics, in a research note on Monday, July 31st. They issued an “overweight” rating and a $24.00 target price on the stock. Finally, BidaskClub upgraded Cytokinetics, from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Cytokinetics, currently has an average rating of “Buy” and an average price target of $21.30.

In other news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $13.62, for a total value of $68,100.00. Following the sale, the chief executive officer now directly owns 94,785 shares of the company’s stock, valued at $1,290,971.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Caryn Gordon Mcdowell sold 11,348 shares of Cytokinetics, stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $12.47, for a total value of $141,509.56. Following the completion of the sale, the insider now directly owns 21,570 shares in the company, valued at $268,977.90. The disclosure for this sale can be found here. Insiders sold 26,348 shares of company stock worth $339,260 over the last ninety days. Insiders own 7.20% of the company’s stock.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTK).

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.